Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma

1. Rodriguez-Abreu, D, Bordoni, A, Zucca, E. Epidemiology of hematological malignancies. Ann Oncol 2007; 18(Suppl. 1): i3–i8.
Google Scholar | Crossref | Medline2. Chaganti, S, Illidge, T, Barrington, S, et al. Guidelines for the management of diffuse large B-cell lymphoma. Br J Haematol 2016; 174: 43–56.
Google Scholar | Crossref | Medline3. International Non-Hodgkin’s Lymphoma Prognostic Factors Project . A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993; 329: 987–994.
Google Scholar | Crossref | Medline4. Rosenwald, A, Wright, G, Chan, WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937–1947.
Google Scholar | Crossref | Medline | ISI5. Alizadeh, AA, Eisen, MB, Davis, RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511.
Google Scholar | Crossref | Medline | ISI6. Thieblemont, C, Briere, J, Mounier, N, et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol 2011; 29: 4079–4087.
Google Scholar | Crossref | Medline | ISI7. Hu, S, Xu-Monette, ZY, Tzankov, A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 2013; 121: 4021–4031; quiz 4250.
Google Scholar8. Akyurek, N, Uner, A, Benekli, M, et al. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Cancer 2012; 118: 4173–4183.
Google Scholar | Crossref | Medline9. Barrans, S, Crouch, S, Smith, A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010; 28: 3360–3365.
Google Scholar | Crossref | Medline | ISI10. Rosenwald, A, Bens, S, Advani, R, et al. Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2019; 37: 3359–3368.
Google Scholar | Crossref | Medline11. Gisselbrecht, C, Glass, B, Mounier, N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 4184–4190.
Google Scholar | Crossref | Medline | ISI12. Nagle, SJ, Woo, K, Schuster, SJ, et al. Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era. Am J Hematol 2013; 88: 890–894.
Google Scholar | Crossref | Medline13. Van Den Neste, E, Schmitz, N, Mounier, N, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplant 2016; 51: 51–57.
Google Scholar | Crossref | Medline14. Glass, B, Hasenkamp, J, Wulf, G, et al. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. Lancet Oncol 2014; 15: 757–766.
Google Scholar | Crossref | Medline15. Kansara, RR, Savage, KJ, Vila, D, et al. Outcome in unselected patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) following R-CHOP when stem cell transplantation is not feasible. Blood 2014; 124: 3069.
Google Scholar | Crossref16. Sehn, LH, Herrera, AF, Flowers, CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2020; 38: 155–165.
Google Scholar | Crossref | Medline17. Salles, G, Duell, J, González Barca, E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol 2020; 21: 978–988.
Google Scholar | Crossref | Medline18. Kalakonda, N, Maerevoet, M, Cavallo, F, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol 2020; 7: e511–e522.
Google Scholar | Crossref | Medline19. Caimi, PF, Ai, W, Alderuccio, JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2021; 22: 790–800.
Google Scholar | Crossref | Medline20. Brudno, JN, Kochenderfer, JN. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol 2018; 15: 31–46.
Google Scholar | Crossref | Medline21. Brentjens, RJ, Latouche, JB, Santos, E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 2003; 9: 279–286.
Google Scholar | Crossref | Medline | ISI22. Kochenderfer, JN, Dudley, ME, Kassim, SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015; 33: 540–549.
Google Scholar | Crossref | Medline | ISI23. Kochenderfer, JN, Somerville, RPT, Lu, T, et al. Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy. Mol Ther 2017; 25: 2245–2253.
Google Scholar | Crossref | Medline24. Neelapu, SS, Locke, FL, Bartlett, NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017; 377: 2531–2544.
Google Scholar | Crossref | Medline25. Locke, FL, Ghobadi, A, Jacobson, CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol 2019; 20: 31–42.
Google Scholar | Crossref | Medline26. Schuster, SJ, Bishop, MR, Tam, CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2019; 380: 45–56.
Google Scholar | Crossref | Medline27. Abramson, JS, Palomba, ML, Gordon, LI, et al. High durable CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T cell product JCAR017 (TRANSCEND NHL 001): defined composition allows for dose-finding and definition of pivotal cohort. Blood 2017; 130(Suppl. 1): 581.
Google Scholar | Medline28. Abramson, JS, Gordon, LI, Palomba, ML, et al. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL. J Clin Oncol 2018; 36(Suppl. 15): 7505.
Google Scholar | Crossref29. Crump, M, Neelapu, SS, Farooq, U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 2017; 130: 1800–1808.
Google Scholar | Crossref | Medline30. Al-Mansour, M, Al-Foheidi, M, Ibrahim, E. Efficacy and safety of second-generation CAR T-cell therapy in diffuse large B-cell lymphoma: a meta-analysis. Mol Clin Oncol 2020; 13: 33.
Google Scholar | Medline31. Loffler, A, Kufer, P, Lutterbüse, R, et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 2000; 95: 2098–2103.
Google Scholar | Crossref | Medline | ISI32. Allen, ES, Stroncek, DF, Ren, J, et al. Autologous lymphapheresis for the production of chimeric antigen receptor T cells. Transfusion 2017; 57: 1133–1141.
Google Scholar | Crossref | Medline33. Vormittag, P, Gunn, R, Ghorashian, S, et al. A guide to manufacturing CAR T cell therapies. Curr Opin Biotechnol 2018; 53: 164–181.
Google Scholar | Crossref | Medline34. Hollyman, D, Stefanski, J, Przybylowski, M, et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother 2009; 32: 169–180.
Google Scholar | Crossref | Medline35. Wang, X, Rivière, I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics 2016; 3: 16015.
Google Scholar | Crossref | Medline36. Cheng, Z, Wei, R, Ma, Q, et al. In vivo expansion and antitumor activity of coinfused CD28- and 4-1BB-engineered CAR-T cells in patients with B cell leukemia. Mol Ther 2018; 26: 976–985.
Google Scholar | Crossref | Medline37. Giavridis, T, Van Der Stegen, SJC, Eyquem, J, et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med 2018; 24: 731–738.
Google Scholar | Crossref | Medline38. Engelberts, PJ, Hiemstra, IH, De Jong, B, et al. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine 2020; 52: 102625.
Google Scholar | Crossref | Medline39. Van Der Horst, HJ, De Jonge, B, Hiemstra, IH, et al. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. Blood Cancer J 2021; 11: 38.
Google Scholar | Crossref | Medline40. Hutchings, M, Mous, R, Clausen, MR, et al. Subcutaneous epcoritamab induces complete responses with an encouraging safety profile across relapsed/refractory B-cell non-Hodgkin lymphoma subtypes, including patients with prior CAR-T therapy: updated dose escalation data. Blood 2020; 136: 45–46.
Google Scholar | Crossref41. Hutchings, M, Morschhauser, F, Iacoboni, G, et al. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J Clin Oncol 2021; 39: 1959–1970.
Google Scholar | Crossref | Medline42. Schuster, SJ, Bartlett, NL, Assouline, S, et al. Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines. Blood 2019; 134(Suppl. 1): 6.
Google Scholar | Crossref | Medline43. Phillips, TJ, Olszewski, AJ, Munoz, J, et al. Mosunetuzumab, a novel CD20/CD3 bispecific antibody, in combination with CHOP confers high response rates in patients with diffuse large B-cell lymphoma. Blood 2020; 136(Suppl. 1): 37–38.
Google Scholar | Crossref44. Bannerji, R, Allan, JN, Arnason, JE, et al. Odronextamab (REGN1979), a human CD20 x CD3 bispecific antibody, induces durable, complete responses in patients with highly refractory B-cell non-Hodgkin lymphoma, including patients refractory to CAR T therapy. Blood 2020; 136: 42–43.
Google Scholar | Crossref45. Wudhikarn, K, Pennisi, M, Garcia-Recio, M, et al. DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. Blood Adv 2020; 4: 3024–3033.
Google Scholar | Crossref | Medline46. Liu, E, Marin, D, Banerjee, P, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med 2020; 382: 545–553.
Google Scholar | Crossref | Medline47. Neelapu, SS, Dickinson, M, Ulrickson, ML, et al. Interim analysis of ZUMA-12: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) as first-line therapy in patients (Pts) with high-risk large B cell lymphoma (LBCL). Blood 2020; 136(Suppl. 1): 49.

留言 (0)

沒有登入
gif